{"title":"2008 至 2022 年巴西镰状细胞病的流行病学概况趋势和费用。","authors":"Luiza Telles, Paulo Henrique Moreira Melo, Gabriele Eckerdt Lech, Luana Baptistele Dornelas, Natália Zaneti Sampaio, Ayla Gerk, Madeleine Carroll, Cristina Camargo","doi":"10.1590/acb403025","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the epidemiological profile trends and economic impact of sickle cell disease (SCD) in Brazil from 2008 to 2022, focusing on incidence, mortality, and healthcare costs.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted using data from the Fundação Oswaldo Cruz's platform, Plataforma de Ciência de Dados Aplicada à Saúde, encompassing hospitalizations related to SCD from January 2008 to December 2022. The International Classification of Diseases codes for SCD were used to retrieve data on incidence, mortality, procedures performed, and healthcare costs.</p><p><strong>Results: </strong>The study included 151,535 hospitalizations for SCD, with 69.92% associated with SCD crises and 22.48% without crises. The mean annual hospitalizations were higher for crises (6,883.06) compared to those without crises (2,221.12). Mortality rates were significantly higher for patients hospitalized with crises compared to those without crises (p < 0.001). The economic impact of SCD was substantial, with annual costs exceeding 413 million USD.</p><p><strong>Conclusion: </strong>This study revealed a significant burden of SCD in Brazil, characterized by high hospitalization rates, particularly among younger patients, and elevated mortality rates associated with crises. Prospective studies and public health interventions are warranted to address SCD and mitigate its impact on public health.</p>","PeriodicalId":93850,"journal":{"name":"Acta cirurgica brasileira","volume":"40 ","pages":"e403025"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960578/pdf/","citationCount":"0","resultStr":"{\"title\":\"Epidemiological profile trends and cost of sickle cell disease in Brazil from 2008 to 2022.\",\"authors\":\"Luiza Telles, Paulo Henrique Moreira Melo, Gabriele Eckerdt Lech, Luana Baptistele Dornelas, Natália Zaneti Sampaio, Ayla Gerk, Madeleine Carroll, Cristina Camargo\",\"doi\":\"10.1590/acb403025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to evaluate the epidemiological profile trends and economic impact of sickle cell disease (SCD) in Brazil from 2008 to 2022, focusing on incidence, mortality, and healthcare costs.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted using data from the Fundação Oswaldo Cruz's platform, Plataforma de Ciência de Dados Aplicada à Saúde, encompassing hospitalizations related to SCD from January 2008 to December 2022. The International Classification of Diseases codes for SCD were used to retrieve data on incidence, mortality, procedures performed, and healthcare costs.</p><p><strong>Results: </strong>The study included 151,535 hospitalizations for SCD, with 69.92% associated with SCD crises and 22.48% without crises. The mean annual hospitalizations were higher for crises (6,883.06) compared to those without crises (2,221.12). Mortality rates were significantly higher for patients hospitalized with crises compared to those without crises (p < 0.001). The economic impact of SCD was substantial, with annual costs exceeding 413 million USD.</p><p><strong>Conclusion: </strong>This study revealed a significant burden of SCD in Brazil, characterized by high hospitalization rates, particularly among younger patients, and elevated mortality rates associated with crises. Prospective studies and public health interventions are warranted to address SCD and mitigate its impact on public health.</p>\",\"PeriodicalId\":93850,\"journal\":{\"name\":\"Acta cirurgica brasileira\",\"volume\":\"40 \",\"pages\":\"e403025\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960578/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta cirurgica brasileira\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/acb403025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta cirurgica brasileira","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/acb403025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评估2008年至2022年巴西镰状细胞病(SCD)的流行病学概况、趋势和经济影响,重点关注发病率、死亡率和医疗成本。方法:使用funda o Oswaldo Cruz’s platform (platform aforma de Ciência de Dados applications)的数据进行横断面分析,包括2008年1月至2022年12月与SCD相关的住院病例。使用SCD的国际疾病分类代码检索有关发病率、死亡率、执行的程序和医疗费用的数据。结果:本研究共纳入151535例SCD住院患者,其中69.92%伴有SCD危像,22.48%无危像。危机患者的平均年住院率(6,883.06)高于无危机患者(2,221.12)。危象住院患者的死亡率明显高于无危象住院患者(p < 0.001)。SCD的经济影响是巨大的,每年的成本超过4.13亿美元。结论:这项研究揭示了巴西SCD的重大负担,其特点是住院率高,特别是在年轻患者中,以及与危重相关的死亡率升高。有必要进行前瞻性研究和公共卫生干预,以解决SCD并减轻其对公共卫生的影响。
Epidemiological profile trends and cost of sickle cell disease in Brazil from 2008 to 2022.
Purpose: This study aimed to evaluate the epidemiological profile trends and economic impact of sickle cell disease (SCD) in Brazil from 2008 to 2022, focusing on incidence, mortality, and healthcare costs.
Methods: A cross-sectional analysis was conducted using data from the Fundação Oswaldo Cruz's platform, Plataforma de Ciência de Dados Aplicada à Saúde, encompassing hospitalizations related to SCD from January 2008 to December 2022. The International Classification of Diseases codes for SCD were used to retrieve data on incidence, mortality, procedures performed, and healthcare costs.
Results: The study included 151,535 hospitalizations for SCD, with 69.92% associated with SCD crises and 22.48% without crises. The mean annual hospitalizations were higher for crises (6,883.06) compared to those without crises (2,221.12). Mortality rates were significantly higher for patients hospitalized with crises compared to those without crises (p < 0.001). The economic impact of SCD was substantial, with annual costs exceeding 413 million USD.
Conclusion: This study revealed a significant burden of SCD in Brazil, characterized by high hospitalization rates, particularly among younger patients, and elevated mortality rates associated with crises. Prospective studies and public health interventions are warranted to address SCD and mitigate its impact on public health.